Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rheumatologic Disorder Clear all
Completed Phase 1Phase 2 Interventional

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

NCT00710333
View directory record Official record
Conditions
Keloid
Interventions
Avotermin, placebo
Drug
Lead sponsor
Renovo
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa

NCT00904163
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Results available

A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome

NCT00622544
View directory record Official record
Conditions
Alport Syndrome, Kidney Disease
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 18 Years · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Short Term Observational Study in DEB Patients

NCT02178969
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional

Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

NCT00987545
View directory record Official record
Conditions
Keloids
Interventions
QAX576, QAX576 placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Paramus, New Jersey • Rochester, New York • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Canakinumab pre-filled syringe, Canakinumab lyophilized powder, Triamcinolone Acetonide, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
69
States / cities
Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Genetic Analysis of Familial Keloids

NCT00008502
View directory record Official record
Conditions
Keloid
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Early Phase 1 Interventional

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

NCT02484053
View directory record Official record
Conditions
Hematologic Disorders, Oncologic Disorders, Rheumatologic Disorders
Interventions
Rituximab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

NCT04844840
View directory record Official record
Conditions
Keloid
Interventions
STP705, Placebo
Drug · Other
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Aventura, Florida • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Web Based Investigation of Natural History of Keloid Disorder, an Online Survey

NCT01423981
View directory record Official record
Conditions
Keloid
Interventions
Not listed
Lead sponsor
Tirgan, Michael H., M.D.
Individual
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Flu Vaccine Response in Patients on Biologic Therapies

NCT03277703
View directory record Official record
Conditions
Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
Interventions
Influenza vaccine
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
3 Years to 22 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
East Setauket, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

NCT03433222
View directory record Official record
Conditions
Skin Diseases, Keloid, Scar, Fibrosis, Hypertrophic Skin
Interventions
HF-LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
VA Northern California Health Care System
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease

NCT02504879
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin

NCT02630303
View directory record Official record
Conditions
Fibrosis, Scarring, Scar, Wounds, Injuries, Keloid, Cicatrix, Hypertrophic
Interventions
LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
Jared Jagdeo, MD, MS
Federal
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of SPY072 in Rheumatic Disease

NCT07148414
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions
SPY002-072, Placebo
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica

NCT00847236
View directory record Official record
Conditions
Polymyalgia Rheumatica, Rheumatoid Arthritis, Rheumatic Disease
Interventions
Not listed
Lead sponsor
Lahey Clinic
Other
Eligibility
50 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Arlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

NCT06563414
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

NCT01538862
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Granulocyte Colony Stimulating Factor (GCSF)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

NCT03232580
View directory record Official record
Conditions
Spondyloarthritis
Interventions
rhAnnexin V-128
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Prademagene Zamikeracel
Combination Product
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

NCT03601052
View directory record Official record
Conditions
Keloid
Interventions
Remlarsen, Placebo
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Aventura, Florida • Chicago, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Computational Drug Repurposing for All EBS Cases

NCT03269474
View directory record Official record
Conditions
Epidermolysis Bullosa, Healthy, Genetic Skin Disease, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions
Experimental Group
Procedure
Lead sponsor
Joyce Teng
Other
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 16, 2026, 10:45 AM EDT